Cargando…
Development, Application, and Results from a Precision-medicine Platform that Personalizes Multi-modal Treatment Plans for Mild Alzheimer’s Disease and At-risk Individuals
INTRODUCTION: Alzheimer’s Disease (AD) is a progressive neurodegenerative condition in which individuals exhibit memory loss, dementia, and impaired metabolism. Nearly all previous sin-gle-treatment studies to treat AD have failed, likely because it is a complex disease with multiple un-derlying dri...
Autores principales: | Keine, Dorothy, Walker, John Q., Kennedy, Brian K., Sabbagh, Marwan N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388425/ https://www.ncbi.nlm.nih.gov/pubmed/30338750 http://dx.doi.org/10.2174/1874609811666181019101430 |
Ejemplares similares
-
Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms
por: Keine, Dorothy, et al.
Publicado: (2019) -
Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012) -
Identifying Alzheimer’s disease and mild cognitive impairment with atlas-based multi-modal metrics
por: Long, Zhuqing, et al.
Publicado: (2023) -
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014) -
Alzheimer’s disease, mild cognitive impairment, and normal aging distinguished by multi-modal parcellation and machine learning
por: Sheng, Jinhua, et al.
Publicado: (2020)